Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt.
Wannhoff A, Hippchen T, Weiss CS, Friedrich K, Rupp C, Neumann-Haefelin C, Dollinger M, Antoni C, Stampfl U, Schemmer P, Stremmel W, Weiss KH, Radeleff B, Katus HA, Gotthardt DN. Wannhoff A, et al. Among authors: antoni c. Aliment Pharmacol Ther. 2016 May;43(9):955-65. doi: 10.1111/apt.13569. Epub 2016 Feb 26. Aliment Pharmacol Ther. 2016. PMID: 26919285 Free article.
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778 Clinical Trial.
PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival.
Friedrich K, Wannhoff A, Kattner S, Brune M, Hov JR, Weiss KH, Antoni C, Dollinger M, Neumann-Haefelin C, Seufferlein T, Schemmer P, Schirmacher P, Stremmel W, Gotthardt DN. Friedrich K, et al. Among authors: antoni c. J Gastroenterol Hepatol. 2014;29(7):1477-84. doi: 10.1111/jgh.12540. J Gastroenterol Hepatol. 2014. PMID: 25273282
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A. Steinebrunner N, et al. Among authors: antoni c. BMC Gastroenterol. 2015 Aug 4;15:97. doi: 10.1186/s12876-015-0328-9. BMC Gastroenterol. 2015. PMID: 26239732 Free PMC article.
The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial.
Casper M, Mengel M, Fuhrmann C, Herrmann E, Appenrodt B, Schiedermaier P, Reichert M, Bruns T, Engelmann C, Grünhage F, Lammert F; INCA trial group. Casper M, et al. Trials. 2015 Mar 8;16:83. doi: 10.1186/s13063-015-0594-4. Trials. 2015. PMID: 25887140 Free PMC article. Clinical Trial.
135 results